Skip to main content

Table 2 Therapeutic interventions and thrombolytic drugs used in STEMI patient population

From: Prevalence of type 2 diabetes mellitus and association of HbA1c with severity of coronary artery disease in patients presenting as non-diabetic acute coronary syndrome

  N (%)
Therapeutic intervention Thrombolysis 108 (64.30)
Primary PCI 20 (11.90)
Late presentation 36 (21.42)
Thrombolysis contraindicated 04 (2.38)
Total 168 (100)
Thrombolytic drug Streptokinase 49 (45.37)
Tenecteplase 41 (37.97)
Reteplase 18 (16.66)
Total 108 (100)